Abstract
Secretory IgA (SIgA) is the antibody type produced in both mammals and birds that protects the body from infection at mucosal surfaces. While monoclonal IgG antibodies, particularly those against tumor antigens, have received a great deal of attention, both scientific and commercial, as immunotherapeutic agents, the potential of SIgA antibodies has only recently begun to be exploited. Part of the reason for this is that SIgA production in vivo normally requires the cooperation of two different cell types, and single animal cell systems for monoclonal SIgA production are inefficient. Transgenic plants are currently the most productive and economical system for making SIgA. The only monoclonal SIgA to be tested therapeutically in a human clinical trial is a product called CaroRx, made in transgenic tobacco, which is designed to block adherence to teeth of the bacteria that causes cavities. This antibody accumulates to high levels in the leaves of tobacco, where it is located primarily in the endoplasmic reticulum. The antibody can be efficiently purified using the affinity reagent protein G. Topical oral treatment in human subjects was safe and effective. Characterization of the expression, secretion, purification and therapeutic use of this antibody serves as a model for additional plant-made therapeutic SIgA antibodies under development.
Keywords: recombinant monoclonal antibodies, secretory component (sc), immunization, anti-Igg antibodies, immunofluorescence, streptococcus pneumoniae, glycoproteins
Current Pharmaceutical Design
Title: Secretory IgA Antibodies from Plants
Volume: 11 Issue: 19
Author(s): K. L. Wycoff
Affiliation:
Keywords: recombinant monoclonal antibodies, secretory component (sc), immunization, anti-Igg antibodies, immunofluorescence, streptococcus pneumoniae, glycoproteins
Abstract: Secretory IgA (SIgA) is the antibody type produced in both mammals and birds that protects the body from infection at mucosal surfaces. While monoclonal IgG antibodies, particularly those against tumor antigens, have received a great deal of attention, both scientific and commercial, as immunotherapeutic agents, the potential of SIgA antibodies has only recently begun to be exploited. Part of the reason for this is that SIgA production in vivo normally requires the cooperation of two different cell types, and single animal cell systems for monoclonal SIgA production are inefficient. Transgenic plants are currently the most productive and economical system for making SIgA. The only monoclonal SIgA to be tested therapeutically in a human clinical trial is a product called CaroRx, made in transgenic tobacco, which is designed to block adherence to teeth of the bacteria that causes cavities. This antibody accumulates to high levels in the leaves of tobacco, where it is located primarily in the endoplasmic reticulum. The antibody can be efficiently purified using the affinity reagent protein G. Topical oral treatment in human subjects was safe and effective. Characterization of the expression, secretion, purification and therapeutic use of this antibody serves as a model for additional plant-made therapeutic SIgA antibodies under development.
Export Options
About this article
Cite this article as:
Wycoff L. K., Secretory IgA Antibodies from Plants, Current Pharmaceutical Design 2005; 11 (19) . https://dx.doi.org/10.2174/1381612054367508
DOI https://dx.doi.org/10.2174/1381612054367508 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Ability of Melatonin to Counteract Lipid Peroxidation in Biological Membranes
Current Molecular Medicine Old Versus New Anticoagulants: Focus on Pharmacology
Recent Patents on Cardiovascular Drug Discovery In Vivo Apoptosis Imaging Agents and Strategies
Anti-Cancer Agents in Medicinal Chemistry Immunomodulatory Role of Arsenic in Regulatory T Cells
Endocrine, Metabolic & Immune Disorders - Drug Targets Evaluation of Inflammatory Biomarkers in Iranian Patients with Cystic Fibrosis
Current Respiratory Medicine Reviews Immune Disturbances in Chronic Pain: Cause, Consequence or Both?
Current Immunology Reviews (Discontinued) Therapeutic Implications of Immune-endocrine Interactions in the Critically Ill Patients
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Transmembrane Interactions of HIV-1 Vpu and Tetherin
Current HIV Research Opioid Free Anaesthesia and Cancer
Current Pharmaceutical Design Perioperative Management of Antiplatelet-Drugs in Cardiac Surgery
Current Cardiology Reviews Plastid Molecular Pharming II. Production of Biopharmaceuticals by Plastid Transformation
Mini-Reviews in Medicinal Chemistry Novel Protein Targeted Therapy of Metastatic Melanoma
Current Pharmaceutical Design Hepatocellular Carcinoma Diagnostics, Treatments and Potential Theragnostics in the Asia-Pacific
Current Pharmacogenomics and Personalized Medicine Inhibition of Apoptosis in Pediatric Cancer by Survivin
Current Pediatric Reviews Pantothenate Kinase-Associated Neurodegeneration
Current Drug Targets Solid Lipid Nanoparticles (SLNs) Gels for Topical Delivery of Aceclofenac in vitro and in vivo Evaluation
Current Drug Delivery QSAR Study of PARP Inhibitors by GA-MLR, GA-SVM and GA-ANN Approaches
Current Analytical Chemistry Phosphodiesterase Inhibitors as Therapeutics for Traumatic Brain Injury
Current Pharmaceutical Design Imiquimod Increases Cutaneous VEGF Expression in Imiquimod-induced Psoriatic Mouse Model
Current Vascular Pharmacology The Clinical Effectiveness of Magnets for People with Osteoarthritis: A Systematic Review and Meta-analysis
Current Rheumatology Reviews